Patents by Inventor Tassie Collins

Tassie Collins has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and Compositions for the Treatment of Demyelinating Disorders
    Publication number: 20190125702
    Abstract: The present invention provides methods and compositions for repairing and/or maintaining the myelin sheath of neuronal axons in a subject. In particular, the present invention provides compositions comprising one or more TRPV1 agonists exhibiting promyelinating activity for treatment of demyelinating disorders.
    Type: Application
    Filed: March 13, 2017
    Publication date: May 2, 2019
    Applicant: Vitality Biopharma, Inc.
    Inventors: Tassie Collins, Karen Lariosa-Willingham, Jason Dugas, Jay S. Tung, Dmitri Leonoudakis, Elen Rosler
  • Modulation of CCR4 function
    Patent number: 7262204
    Abstract: Compounds and compositions are provided that bind to the CCR4 chemokine receptor and which are useful for treating diseases associated with CCR4 activity, such as contact hypersensitivity.
    Type: Grant
    Filed: September 2, 2003
    Date of Patent: August 28, 2007
    Assignees: Amgen Inc., ChemoCentryx, Inc.
    Inventors: Tassie Collins, Daniel J. Dairaghi, Hossen Mahmud, Brian E. McMaster, Julio C. Medina, Thomas J. Schall, Feng Xu, Xuemei Wang
  • CXCR3 antagonists
    Publication number: 20070149557
    Abstract: Compounds, compositions and methods are provided that are useful in the treatment of conditions and diseases mediated by a chemokine receptor. In particular, the compounds of the invention modulate the CXCR3 chemokine receptor. The subject methods are useful for the treatment of inflammatory and immunoregulatory disorders and diseases, such as multiple sclerosis, rheumatoid arthritis and type I diabetes.
    Type: Application
    Filed: November 21, 2006
    Publication date: June 28, 2007
    Applicant: Amgen Inc.
    Inventors: Tassie Collins, Julio Medina, Feng Xu, Liusheng Zhu
  • CCR4 antagonists
    Patent number: 7144903
    Abstract: Compounds, compositions and methods are provided that are useful in the treatment of chemokine receptor-mediated conditions and diseases. In particular, the invention provides compounds which modulate CCR4 function or a CCR4-mediated response. The subject compounds and compositions are useful for the treatment or prevention of inflammatory conditions and diseases.
    Type: Grant
    Filed: May 22, 2002
    Date of Patent: December 5, 2006
    Assignee: Amgen Inc.
    Inventors: Tassie Collins, Hossen Mahmud, Jonathan Houze, Alan Xi Huang, Julio C. Medina, Xuemei Wang, Feng Xu, Qingge Xu, Liusheng Zhu
  • Modulation of CCR4 function
    Publication number: 20040039035
    Abstract: Compounds and compositions are provided that bind to the CCR4 chemokine receptor and which are useful for treating diseases associated with CCR4 activity, such as contact hypersensitivity.
    Type: Application
    Filed: September 2, 2003
    Publication date: February 26, 2004
    Applicants: Tularik Inc., ChemoCentryx, Inc.
    Inventors: Tassie Collins, Daniel J. Dairaghi, Hossen Mahmud, Brian E. McMaster, Julio C. Medina, Thomas J. Schall, Feng Xu, Xuemei Wang
  • Ccr4 antagonists
    Publication number: 20030018022
    Abstract: Compounds, compositions and methods are provided that are useful in the treatment of chemokine receptor-mediated conditions and diseases. In particular, the invention provides compounds which modulate CCR4 function or a CCR4-mediated response. The subject compounds and compositions are useful for the treatment or prevention of inflammatory conditions and diseases.
    Type: Application
    Filed: May 22, 2002
    Publication date: January 23, 2003
    Applicant: Tularik Inc.
    Inventors: Tassie Collins, Hossen Mahmud, Jonathan Houze, Alan Xi Huang, Julio C. Medina, Xuemei Wang, Feng Xu, Qingge Xu, Liusheng Zhu
  • Modulation of CCR4 function
    Publication number: 20020173524
    Abstract: Compounds and compositions are provided that bind to the CCR4 chemokine receptor and which are useful for treating diseases associated with CCR4 activity, such as contact hypersensitivity.
    Type: Application
    Filed: October 11, 2001
    Publication date: November 21, 2002
    Applicant: Tularik Inc.
    Inventors: Tassie Collins, Daniel J. Dairaghi, Hossen Mahmud, Brian E. McMaster, Julio C. Medina, Thomas J. Schall, Feng Xu, Xuemei Wang